Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.-MedSci.cn

Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.

Da Silva, IP; Ahmed, T; Lo, S; Reijers, ILM; Weppler, A; Warner, AB; Patrinely, JR; Serra-Bellver, P; Lebbe, C; Mangana, J; Nguyen, K; Zimmer, L; Ascierto, PA; Stout, D; Lyle, M; Klein, O; Gerard, CL; Blank, CU; Menzies, AM; Long, GV

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (15):

科室
- - 订阅+
  - 更多科室
工具
服务